Paul Goldman, MD
Emergency Medicine · Fort Worth, TXNPI 1053430975
Payments from drug & device makers
Across 58 payments — averaging $16.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amarin Pharma, Inc.$247
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$100
- Kowa Pharmaceuticals America, Inc.$80
- Pfizer$77
- Takeda Pharmaceuticals U.S.A., Inc.$55
- Johnson & Johnson$54
- plus $346 from 15 others
What the payments were for
- Food & beverage$93097%
- Education$303%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amarin Pharma, Inc. | 12 | $247 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $100 |
| Kowa Pharmaceuticals America, Inc. | 6 | $80 |
| Pfizer | 5 | $77 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $55 |
| Johnson & Johnson | 4 | $54 |
| Amgen | 2 | $41 |
| Alfasigma USA, Inc. | 2 | $38 |
| Ascensia Diabetes Care US Inc. | 1 | $30 |
| Evoke Pharma, Inc. | 2 | $28 |
| Bayer | 2 | $27 |
| Astellas Pharma US Inc | 2 | $26 |
| Medicure Pharma Inc. | 1 | $24 |
| Novartis | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Lilly USA, LLC | 1 | $18 |
| AbbVie | 1 | $18 |
| Globus Medical | 1 | $18 |
| Novo Nordisk | 1 | $15 |
| Althera Pharmaceuticals LLC | 1 | $13 |
| Mylan Specialty L.p. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Vascepa$105
How this compares
$960 in reported general payments places this provider in the 90th percentile of 3,952 emergency medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 83 | $81,821 |
| OzempicSemaglutide | 50 | $51,658 |
| VascepaIcosapent Ethyl | 40 | $23,818 |
| JanuviaSitagliptin Phosphate | 17 | $21,474 |
| LivaloPitavastatin Calcium | 18 | $15,058 |
| EntrestoSacubitril/Valsartan | 18 | $14,025 |
| JentaduetoLinagliptin/Metformin Hcl | 17 | $11,374 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 13 | $10,359 |
| Icosapent Ethyl | 32 | $7,579 |
| TradjentaLinagliptin | 11 | $6,722 |
| MyrbetriqMirabegron | 12 | $6,506 |
| Sucralfate | 23 | $4,076 |
| Potassium Chloride | 131 | $4,002 |
| Nebivolol Hcl | 83 | $3,933 |
| Doxazosin Mesylate | 135 | $3,227 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $77 | $81,82183 claims |
| Novo NordiskOzempic | $15 | $51,65850 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $80 | $15,05818 claims |
| NovartisEntresto | $19 | $14,02518 claims |
| Astellas Pharma US IncMyrbetriq | $26 | $6,50612 claims |
| AbbVieSynthroid | $18 | $1,18315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,952 emergency medicine providers in Texas.
Other emergency medicine in Fort Worth
- J SlaughterFort Worth$29K
- Chad CrystalPalestine$26.8M
- Brian SpearsSan Antonio$12.9M
- Sinikka GreenAustin$10.2M
- James LillyDallas$8.5M
- Craig BoyleAustin$8M
- Alan HandSugar Land$6.8M
- Rebecca Wood-HorrallSmithville$5.9M
- Michael ZimmermanAustin$4.7M
- Bentley BobrowHouston$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.